Kefu Medical's 2025 performance outlook: net profit steadily increasing, Chairman's salary rising, and average employee salary reaching 116,500 yuan

Kefu Medical (301087) recently released its 2025 financial report, showing the company achieved an operating revenue of 3.387 billion yuan for the year, a 13.56% increase compared to the previous year; net profit attributable to shareholders of the parent company reached 372 million yuan, a 19.20% year-over-year growth. This performance continues the growth trend since 2024, indicating the company’s ongoing operational improvement.

In terms of business segments, health monitoring products performed outstandingly, with annual revenue increasing by 20.08%. Notable products such as dual-test strips for blood glucose and uric acid, as well as preheated thermometers, saw significant sales growth. The rehabilitation aids segment grew by 12.68%, with core products like posture correction belts and smart hearing aids maintaining steady growth. The medical care segment saw a revenue increase of 13.76%, with traditional Chinese medicine therapy and other business areas becoming highlights with a 35.14% growth rate.

Looking back at the financial data over the past four years, the company’s net profit declined by 29.65% in 2022 and 15.71% in 2023, but rebounded by 22.60% in 2024 to reach 312 million yuan. In 2025, growth continued, with net profit increasing by 19.20% compared to 2024, demonstrating strong operational resilience.

Regarding management compensation, Chairman and President Zhang Min received a pre-tax salary of 1.6786 million yuan in 2025, up 328,700 yuan from 1.3499 million yuan in 2024. Public information shows that this 1979-born master’s degree holder has extensive experience in the medical device industry, having served as an executive in multiple related companies. He also currently holds positions such as Executive Director of Changsha Medical Investment Co., Ltd.

Based on financial estimates, Kefu Medical’s average employee salary in 2025 is approximately 116,500 yuan. As a medical device company focused on personal health management, it has established a comprehensive business system covering five major product lines: health monitoring, rehabilitation aids, respiratory support, medical care, and traditional Chinese medicine therapy.